Incidence and Recurrence of Melanoma Are Equivalent
the Cancer Therapy Advisor take:
Findings presented at the American Academy of Dermatology summer meeting showed a similar rate of diagnosis of in situ or invasive melanoma compared with the long-term risk of invasive melanoma recurrence.
A diagnosis of invasive melanoma compared with a diagnosis of in situ melanoma had an increased risk of invasive recurrence within 2 years of diagnosis. After that 2 year window, the risk of invasive recurrence was equivalent to the risk of diagnosis of either disease.
As a result, the follow-up for patients with in situ melanoma or invasive melanoma should be identical. The 40-year retrospective study used data from the Surveillance, Epidemiology, and End Results (SEER) program for 1973 to 2011.
Investigators identified 55,661 patients with a diagnosis of in situ melanoma, 97,614 patients with locally invasive melanoma, and 14,999 patients with regional or distant invasive melanoma. Those with a diagnosis of in situ melanoma had a hazard of invasive recurrence of 1.0, while the localized group and the regional/distant group had a hazard ratio of 1.03 and 1.08, respectively.
Diagnosis of in situ or invasive conferred a similar long-term risk of invasive melanoma recurrence.
Thereafter, the risk of invasive recurrence remains the same, regardless of the initial diagnosis, Hyemin Pomerantz, MD, of Brown University in Providence, R.I., reported here at the American Academy of Dermatology summer meeting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
- Expert Panel Provides Recommendations for Running Trials on Intratumoral Immunotherapy
- Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments
- Treatment of H. pylori Increased Platelet Count in ITP
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population